ангиотензин II 受体对抗剂 抗生素对抗剂
1Department of Medicine, Centre Hospitalier Universitaire, Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
Lancet (London, England)
|March 4, 2000
概括
新的血管激素II受体对抗剂比较老的血管激素转化酶 (ACE) 抑制剂提供了更具特异性的宁-血管激素系统阻断. 这些药物在高血压患者中表现出相似的疗效,并可能在预防心血管疾病方面提供未来的好处.
科学领域:
- 药理学和心血管医学.
- 药物开发和治疗学
背景情况:
- 氨酸 - - ангиотензин系统 (RAS) 是心血管功能的一个关键调节器.
- 早期的研究利用药理学探针来研究RAS,这导致了血管激素转化酶 (ACE) 抑制剂的开发.
- 虽然ACE抑制剂是有效的,但它们针对RAS级联中的非特异性酶.
研究的目的:
- 介绍和评估口服活跃的血管激素II受体对抗剂的意义.
- 为了比较 ангиотензин II 受体对抗剂与现有的 ACE 抑制剂的疗效.
- 探索血管激素II受体对抗剂在预防位器官损伤和减少心血管事件方面的潜力.
主要方法:
- 对药理学探针及其演变为治疗剂的审查.
- 对口服活性的血管新素II受体抗剂的开发和市场可用性的分析.
- 血管新素II受体对抗剂和ACE抑制剂之间的临床疗效数据的比较,特别是在高血压患者中.
主要成果:
- 与ACE抑制剂相比, ангиотензинII受体对抗剂提供了更具特异性的RAS阻断.
- 目前的数据表明,血管增生素II受体对抗剂在治疗高血压方面与ACE抑制剂同样有效.
- 有几种 ангиотензин II 受体对抗剂在商业上可用,更多的正在开发中.
结论:
- ангиотензинII受体对抗剂代表了RAS阻断的显著进展,提供了更大的特异性.
- 这些药物是一种可行的治疗选择,在高血压患者中表现出与ACE抑制剂相当的疗效.
- 目前正在进行的试验至关重要,以确定血管激素II受体对抗剂是否可以在预防长期心血管并发症方面超过ACE抑制剂.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...